Valley Diagnostics is bringing to market next generation lateral flow diagnostic kits, combined with smartphone technology for reading test results and software for capturing and managing subject data, all for deployment in screening programs, in “point-of-care” and “at-home” use. Valley Diagnostics lateral flow devices will test for patent-protected biomarkers that identify early human and animal diseases allowing for very early detection and diagnosis of disease. Our team includes world renowned metabolomics researchers, experts in antigenic translation, antibody development and production, assay development and production, novel lateral flow technology, machine learning and user facing mobile app technology and data capture systems. We manage the whole product development lifecycle, from biomarker fingerprinting with the highest AUC, followed by the applied chemistry process to translate analytes into antibodies and produce them at scale. We then conjugate the antibodies to produce the immunoassay for building into a lateral flow test using latest lateral flow test smart fluidics to detect multiple analytes in one test. We apply regulator-approved Computer Vision and Machine Learning algorithms deployed via smartphone apps and cloud-based computing to capture, manage, analyse and report test result data with an app, cloud and dashboard software platform designed for medical-grade regulatory compliance. "We want to make a difference to human and animal healthcare, to help identify disease early, to enable intervention when it can make a real difference" - Dave Taylor. Founder and CEO We are very pleased to announce that Valley Diagnostics Ltd has acquired the assets of Bond Digital Health. We are really looking forward to continuing the fantastic work that BDH did with the TRANSFORM platform and its other projects. Watch this space for news and updates!